A comparative study on the effect of docetaxel-albumin nanoparticles and docetaxel-loaded PEG-albumin nanoparticles against non-small cell lung cancer

  • Authors:
    • Guangming Jin
    • Mingji Jin
    • Xuezhe Yin
    • Zhehu Jin
    • Liqing Chen
    • Zhonggao Gao
  • View Affiliations

  • Published online on: September 18, 2015     https://doi.org/10.3892/ijo.2015.3174
  • Pages: 1945-1953
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study mainly compared the effect of docetaxel-albumin nanoparticles (DANPs) and docetaxel-loaded PEG-albumin nanoparticles (PEG-DANPs) against non-small cell lung cancer (NSCLC). We made systematic assessments on these three drugs against NSCLC both in vitro and in vivo. With the purpose of eliminating side-effects of the commercial formulation (Tween-80) and prolonging the blood circulation time, we used emulsion-evaporation cross-link method to prepare DANPs and PEG-DANPs. The DANPs had an average particle size of 163.4±3.76 nm, a zeta potential of -19.4±0.18 mV, a polydispersity index of 0.143±0.03, a drug loading of 8.71±0.98%, and an encapsulation efficiency of 93.58±0.86%; the average particle size of PEG-DANPs is 169.19±2.36 nm, zeta potential is -18.2±0.21 mV, with a polydispersity index of 1.56±0.05, a drug loading of 8.72±1.05% and an encapsulation efficiency of 95.4±5.5%. PEG-DANPs showed a dose- and time-dependent efficacy in cytotoxicity studies in vitro; the hemolysis test indicated that PEG-DANPs had less hemocytolysis than Aisu® and DANPs; in addition, a more prolonged circulation time and sustained in vitro release behavior were observed in the PEG-DANPs compared with Aisu® and DANPs; the cellular uptake test in vitro demonstrated that PEG-DANPs could be absorbed easier into the nucleus; furthermore, the tumor growth of NSCLC-bearing nude mice in vivo was reduced the most by PEG-DANPs. In conclusion, the PEG-DANPs have the lowest side-effects, the highest antitumor activity with the longest blood circulation time of the three drugs, and it will provide an alternative to patients with NSCLC.
View Figures
View References

Related Articles

Journal Cover

November-2015
Volume 47 Issue 5

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Jin G, Jin M, Yin X, Jin Z, Chen L and Gao Z: A comparative study on the effect of docetaxel-albumin nanoparticles and docetaxel-loaded PEG-albumin nanoparticles against non-small cell lung cancer. Int J Oncol 47: 1945-1953, 2015
APA
Jin, G., Jin, M., Yin, X., Jin, Z., Chen, L., & Gao, Z. (2015). A comparative study on the effect of docetaxel-albumin nanoparticles and docetaxel-loaded PEG-albumin nanoparticles against non-small cell lung cancer. International Journal of Oncology, 47, 1945-1953. https://doi.org/10.3892/ijo.2015.3174
MLA
Jin, G., Jin, M., Yin, X., Jin, Z., Chen, L., Gao, Z."A comparative study on the effect of docetaxel-albumin nanoparticles and docetaxel-loaded PEG-albumin nanoparticles against non-small cell lung cancer". International Journal of Oncology 47.5 (2015): 1945-1953.
Chicago
Jin, G., Jin, M., Yin, X., Jin, Z., Chen, L., Gao, Z."A comparative study on the effect of docetaxel-albumin nanoparticles and docetaxel-loaded PEG-albumin nanoparticles against non-small cell lung cancer". International Journal of Oncology 47, no. 5 (2015): 1945-1953. https://doi.org/10.3892/ijo.2015.3174